In particular, ANGPTL6 levels were upregulated in patients with obesity and type 2 diabetes, which are positively correlated with the fasting serum glucose concentration and preceding the development of representative metabolic syndrome symptoms, including dyslipidemia (low HDL and high plasma TG levels) [135,138]. Here, ANGPTL6 is linked to metabolic syndrome.